The Swedish Research Council invests SEK 25 million in ENABLE-2
2022-12-13
ENABLE-2 receives continued funding from the Swedish Research Council, now allocating SEK 25 million to the platform's second year of operations. "We are about to open a second call in order to complement our portfolio with additional projects," says Anders Karlén, Coordinator of ENABLE-2 and Professor at Uppsala University.
ENABLE-2 is a platform with its hub at Uppsala University's Faculty of Pharmacy that provides support for development of a number of promising candidates for antibacterial drugs. With the Swedish Research Council's initial funding for the operation expiring 31 December 2022, the Council recently announced that ENABLE-2 will receive an additional SEK 25 million for the upcoming calendar year.
“I warmly welcome this decision from the Swedish Research Council's. Drug development takes many years, and the fact that our grant have been renewed is an important step in securing the long-term sustainability of ENABLE-2. Today, our platform is in full operation and the programmes we support are progressing quickly. Therefore, around New Years, we will have a second open call for proposals with the aim to, as soon as possible, add new programmes to our portfolio,” says Anders Karlén, Coordinator of ENABLE-2.
The platform's first call in the autumn of 2021 received a positive response from Sweden's universities and biotech companies. In this second round, interest is expected to be just as strong, with the hope of finding a molecule that will lead to the first novel antibiotic class reaching patients since 1984.
“The development of new antibiotics is central in facing the challenges associated with resistant bacteria, and today the needs are so urgent that intensified work in this area is required. We are currently looking into the possibility to include the rest of Europe in our upcoming call, as a larger geographical coverage will increase our chances of extracting the greatest possible value,” says Anders Karlén.
FACTS
- ENABLE-2 is a national platform that offers project support in the development of antibacterial drugs.
- ENABLE-2 is coordinated at the Faculty of Pharmacy, Uppsala University.
LEARN MORE
CONTACT
Anders Karlén, Professor
Faculty of Pharmacy
Anders.Karlen@ilk.uu.se
Text: Magnus Alsne, photo: Mikael Wallerstedt
ENABLE-2 News and media coverage
-
ENABLE-2 Open Call raising international interest
2023-01-18
“We welcome the great international interest shown in our platform", states Anders Karlén, coordinator of ENABLE-2 that in a recent call for proposals received applications from six European countries.
-
Läkemedelsvärlden: Enable-2 får fortsatt finansiering 2023
2022-12-20
Läkemedelsvärlden, 2022-12-20
-
Anders Karlén in Lif podcast: Antibiotic resistance - the silent pandemic
2022-12-19
Anders Karlén, Professor of Computational Medicinal Chemistry and coordinator of ENABLE 2, and Årets läkemedelsprofil (Pharmaceutical Drug Profile of the Year) Enrico Baraldi discuss Antibiotic resistance - the silent pandemic in a new episode of Lif:s Podden. Antibiotic expert Bengt Mattson and Pod host Amy Havenäng, both Lif, also participate in the conversation (note: pod in Swedish)
-
The Swedish Research Council invests SEK 25 million in ENABLE-2
2022-12-13
ENABLE-2 receives continued funding from the Swedish Research Council, now allocating SEK 25 million to the platform's second year of operations. "We are about to open a second call in order to complement our portfolio with additional projects," says Anders Karlén, Coordinator of ENABLE-2 and Professor at Uppsala University.
-
ENABLE-2 partner Uppsala University publishes patent application
2022-12-05
ENABLE-2 partner Uppsala University has published a first patent application on a series of compounds targeting the LpxH enzyme and showing highly potent in vivo activity. These compounds are active against wild-type bacterial cells, including carbapenem-resistant clinical isolates, and show very good efficacy in clearing infections in mouse models.
-
Anders Karlén guest in Forskarpodden: The Fight Against Antibiotic Resistance
2022-11-22
In The Fight against Antibiotic Resistance, the new episode of Forskarpodden, Anders Karlén, Professor and Coordinator of ENABLE-2, and Dan I Andersson, Professor of Medical Bacteriology, discuss the current efforts at Uppsala University to fight the challenges of accelerating antibiotic resistance. (Note: Pod in Swedish)
-
Akut behov av breda lösningar mot antibiotikaresistens
2022-11-16
Vinnova.2022-11-16
-
Luke Odell promoted to Professor of Medicinal Chemistry
2022-11-14
ENABLE-2 and The Faculty of Pharmacy congratulates Luke Odell on his promotion to Professor of Medicinal Chemistry at Uppsala University. “Research is a joint effort, so this is a recognition that our entire team can take pride in,” states Luke Odell, leader of ENABLE-2 project QuinGiT.
-
ENABLE-2 has accepted a new program from Thioredoxin Systems AB
2022-09-30
We are happy to announce that ENABLE-2 has accepted a new program to assist Thioredoxin Systems AB in the development of their EbsArgent product.
-
Researcher profile: Anders Karlén coordinates the combat against the invisible enemy
2022-06-11
“As long as disaster does not strike with full force, many prefer to look elsewhere,” says Anders Karlén, Professor of Computer-Aided Drug Design, who after coordinating the European flagship ENABLE now continues the fight against antibiotic-resistant bacteria within the framework of the international platform ENABLE -2.
-
”Morötter till industrin löser inte bristen på nya antibiotika”
2022-05-23
Dagens Medicin, 2022-05-23
-
ENABLE-2 satsar på fyra projekt om nya antibiotika
2022-03-29
LäkemedelsVärlden, 2022-03-29
-
Alumnus in focus: Malin Grape is the world's first AMR Ambassador
2022-03-28
“Sweden has a very distinctive voice in antibiotic matters that both the EU and the world listen to, and we must use it," states Malin Grape, Swedish ambassador against antimicrobial resistance and alumnus at the Faculty of Pharmacy.
-
QureTech Bio får stort stöd för fortsatt utveckling av nya antibiotika
2022-03-23
Umeåbaserade QureTech Bio AB får stöd av Vetenskapsrådets storsatsning ENABLE-2, som i samarbete med Vinnova även ger små och medelstora företag tillgång till ENABLE-2-plattformen för att fortsätta jakten på nya antibiotika. Plattformen tillhandhåller resurser i form av experimentellt arbete och erfarenhet inom antibiotikautvecklingens tidiga stadier.
-
ENABLE-2 takes the lead in the pursuit of new antibiotics
2022-03-21
The Swedish Research Council's investment in ENABLE-2 has, with support from Vinnova, launched with four projects that are considered very promising in the pursuit for new antibiotics. In the first round of admissions, two projects from Uppsala University, and one each from Linköping University and the biotech company QureTech Bio AB were selected for development.
-
ENABLE-2 ready to lead continued development of new antibiotics
2021-12-21
ENABLE, the EU initiative for antibiotic development led by Uppsala University, will continue its work in ENABLE-2 with financial support from the Swedish Research Council. "An independent committee have chosen between many interesting project proposals and the platform is now entering operational phase," says Anders Karlén, Professor at the Faculty of Pharmacy.
-
SciLifeLab part of ENABLE-2, an international collaboration to combat antimicrobial resistance
2021-10-18
SciLifeLab, 2021-10-18
-
Forskningspengar att söka för nya antibiotika
2021-10-07
LäkemedelsVärlden, 2021-10-07
-
SEK 25 million to ENABLE-2 and continued development of new antibiotics
2021-10-05
ENABLE, the EU initiative for antibiotic development led by Uppsala University, has received SEK 25 million from the Swedish Research Council to start up ENABLE-2. "We are already accepting project proposals and hope that this investment will inspire more financiers," says coordinator Anders Karlén.
-
Nya pengar till svenskledd satsning på nya antibiotika
2021-03-10
LäkemedelsVärlden, 2021-03-10
Learn more about current & previous events at ENABLE-2